FindMyKOL
Clinical trialNCT04993261Active, not recruitingPhase Early 1Interventional

An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors

NCT04993261 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. As of 21 Nov 2026, it is active and no longer recruiting. It studies Carcinoid Syndrome, Carcinoid Tumor and 2 more conditions. The registry lists an enrollment of 71 participants at 1 site in 1 country. The registry lists a start date of 23 Sept 2015 and a primary completion date of 31 Dec 2026.

SponsorM.D. Anderson Cancer CenterEnrollment71Carcinoid SyndromeCarcinoid TumorDigestive System Neuroendocrine Tumor G1Metastatic Carcinoid Tumor
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT04993261
FieldValue
Registry IDNCT04993261
StatusActive not recruiting
PhasePhase Early 1
Study typeInterventional trial
Lead sponsorM.D. Anderson Cancer Center
Enrollment71
Registered sites1
Countries1
ConditionsCarcinoid Syndrome, Carcinoid Tumor, Digestive System Neuroendocrine Tumor G1 and Metastatic Carcinoid Tumor
Start23 Sept 2015
Primary completion31 Dec 2026
Study completion31 Dec 2026
Last update posted11 Aug 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This trial studies the use of a special type of computed (CT) scan called dual energy CT in detecting gastrointestinal carcinoid tumors. CT is an imaging technique that uses x-rays and a computer to create images of areas inside the body. Dual energy computed tomography is a technique used during routine CT scans to help obtain and process the image after the scan is complete. Doctors want to learn if dual energy computed tomography can help improve the detection of carcinoid tumors during routine CT scans.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Texas, United States1 site
  • M D Anderson Cancer Center

    Houston

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexas: 1 siteTX1FloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Questions about NCT04993261

Each answer restates registry values shown on this page.

What is NCT04993261?

NCT04993261 is a phase early 1 interventional trial sponsored by M.D. Anderson Cancer Center. It studies Carcinoid Syndrome, Carcinoid Tumor and 2 more conditions.

Is NCT04993261 recruiting?

As of 21 Nov 2026, it is active and no longer recruiting.

Who leads NCT04993261?

The registry names Ajaykumar Morani (principal investigator, M.D. Anderson Cancer Center) as the overall official.

Where does NCT04993261 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

When is NCT04993261 expected to complete?

The registry lists a primary completion date of 31 Dec 2026 and a study completion date of 31 Dec 2026. The sponsor last updated the record on 11 Aug 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.